Literature DB >> 35046548

On label bevacizumab for retina: where it stands.

Ashish Sharma1, Nilesh Kumar2,3, Nikulaa Parachuri2,4, Anat Loewenstein5, Francesco Bandello6, Baruch D Kuppermann7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35046548      PMCID： PMC9046423          DOI： 10.1038/s41433-021-01909-z

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  4 in total

1.  Estimating Medicare and Patient Savings From the Use of Bevacizumab for the Treatment of Exudative Age-related Macular Degeneration.

Authors:  Philip J Rosenfeld; Matthew A Windsor; William J Feuer; Sissi J J Sun; Kevin D Frick; Eric A Swanson; David Huang
Journal:  Am J Ophthalmol       Date:  2018-04-12       Impact factor: 5.258

2.  Off-label use of bevacizumab for wet age-related macular degeneration in Europe.

Authors:  Tomas Bro; Magdalena Derebecka; Øystein Kalsnes Jørstad; Andrzej Grzybowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-30       Impact factor: 3.117

Review 3.  Biosimilars for Retinal Diseases: An Update.

Authors:  Ashish Sharma; Nilesh Kumar; Nikulaa Parachuri; Francesco Bandello; Baruch D Kuppermann; Anat Loewenstein
Journal:  Am J Ophthalmol       Date:  2020-12-09       Impact factor: 5.258

4.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.

Authors:  Carl D Regillo; David M Brown; Prema Abraham; Huibin Yue; Tsontcho Ianchulev; Susan Schneider; Naveed Shams
Journal:  Am J Ophthalmol       Date:  2008-02       Impact factor: 5.258
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.